RNS60 在肌萎缩侧索硬化症中的初步试验。
A pilot trial of RNS60 in amyotrophic lateral sclerosis.
机构信息
Neurological Clinical Research Institute, Massachusetts General Hospital, 165 Cambridge Street, Suite 600, Boston, Massachusetts, 02114, USA.
Spaulding Rehabilitation Hospital, Boston, Massachusetts, USA.
出版信息
Muscle Nerve. 2019 Mar;59(3):303-308. doi: 10.1002/mus.26385. Epub 2018 Dec 26.
Abstract
INTRODUCTION
RNS60 is a novel immune-modulatory agent that has shown neuroprotective effects in amytrophic lateral sclerosis (ALS) preclinical models. RNS60 is administered by weekly intravenous infusion and daily nebulization. The objective of this pilot open-label trial was to test the feasibility, safety, and tolerability of long-term RNS60 administration in ALS patients.
METHODS
The planned treatment duration was 23 weeks and the primary outcomes were safety and tolerability. Secondary outcomes included PBR28 positron emission tomography (PET) imaging and plasma biomarkers of inflammation.
RESULTS
Sixteen participants with ALS received RNS60 and 13 (81%) completed 23 weeks of RNS60 treatment. There were no serious adverse events and no participants withdrew from the trial due to drug-related adverse events. There were no significant changes in the biomarkers.
DISCUSSION
Long-term RNS60 administration was safe and well-tolerated. A large, multicenter, phase II trial of RNS60 is currently enrolling participants to test the effects of RNS60 on ALS biomarkers and disease progression. Muscle Nerve 59:303-308, 2019.
摘要
简介
RNS60 是一种新型免疫调节药物，在肌萎缩侧索硬化症（ALS）的临床前模型中显示出神经保护作用。RNS60 通过每周静脉输注和每日雾化给药。本试验的目的是测试 RNS60 在 ALS 患者中的长期给药的可行性、安全性和耐受性。
方法
计划的治疗时间为 23 周，主要终点是安全性和耐受性。次要终点包括 PBR28 正电子发射断层扫描（PET）成像和炎症的血浆生物标志物。
结果
16 名 ALS 患者接受了 RNS60 治疗，其中 13 名（81%）完成了 23 周的 RNS60 治疗。没有严重的不良事件，也没有因药物相关不良事件而退出试验的患者。生物标志物没有明显变化。
讨论
长期 RNS60 给药是安全且耐受良好的。一项针对 RNS60 的大型、多中心、二期临床试验目前正在招募参与者，以测试 RNS60 对 ALS 生物标志物和疾病进展的影响。肌肉神经 59:303-308, 2019。
相似文献
1
A pilot trial of RNS60 in amyotrophic lateral sclerosis.RNS60 在肌萎缩侧索硬化症中的初步试验。
Muscle Nerve. 2019 Mar;59(3):303-308. doi: 10.1002/mus.26385. Epub 2018 Dec 26.
2
Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.RNS60 在肌萎缩侧索硬化症中的作用：一项 II 期多中心、随机、双盲、安慰剂对照试验。
Eur J Neurol. 2023 Jan;30(1):69-86. doi: 10.1111/ene.15573. Epub 2022 Oct 7.
3
RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue.RNS60 通过保护神经胶质细胞和周围神经来发挥治疗作用，对 SOD1 ALS 模型小鼠有效。
J Neuroinflammation. 2018 Mar 1;15(1):65. doi: 10.1186/s12974-018-1101-0.
4
Long-term survival of participants in a phase II randomized trial of RNS60 in amyotrophic lateral sclerosis.RNS60 治疗肌萎缩侧索硬化症的 II 期随机试验参与者的长期生存。
Brain Behav Immun. 2024 Nov;122:456-462. doi: 10.1016/j.bbi.2024.08.044. Epub 2024 Aug 28.
5
Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial.在肌萎缩侧索硬化症中使用 Triumeq 的安全性和耐受性：灯塔试验。
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(7-8):595-604. doi: 10.1080/21678421.2019.1632899. Epub 2019 Jul 8.
6
Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.依达拉奉（MN-166）治疗肌萎缩侧索硬化症的开放性标签安全性和药效学研究。
Neuroimage Clin. 2021;30:102672. doi: 10.1016/j.nicl.2021.102672. Epub 2021 Apr 15.
7
Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.肌萎缩侧索硬化症患者体内胶质细胞激活增加：用[(11)C]-PBR28评估
Neuroimage Clin. 2015 Jan 19;7:409-14. doi: 10.1016/j.nicl.2015.01.009. eCollection 2015.
8
Integrated imaging of [C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy H-MRS in amyotrophic lateral sclerosis.肌萎缩侧索硬化症的 [C]-PBR28 PET、MR 扩散和磁共振波谱 H-MRS 联合成像。
Neuroimage Clin. 2018 Aug 9;20:357-364. doi: 10.1016/j.nicl.2018.08.007. eCollection 2018.
9
Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.肌萎缩侧索硬化症患者的美卡辛治疗：一项随机对照试验的研究方案
Trials. 2018 Apr 13;19(1):225. doi: 10.1186/s13063-018-2557-z.
10
Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial.氟卡尼在肌萎缩侧索硬化症中的神经保护作用（FANS）：一项随机安慰剂对照试验。
EBioMedicine. 2015 Dec 1;2(12):1916-22. doi: 10.1016/j.ebiom.2015.11.022. eCollection 2015 Dec.
引用本文的文献
1
An Expanded Access Protocol of RNS60 in Amyotrophic Lateral Sclerosis.RNS60在肌萎缩侧索硬化症中的扩大使用协议
Muscle Nerve. 2025 Mar 21. doi: 10.1002/mus.28398.
2
Induction of FoxP3 Pre-mRNA Alternative Splicing to Enhance the Suppressive Activity of Regulatory T Cells from Amyotrophic Lateral Sclerosis Patients.诱导FoxP3前体信使核糖核酸可变剪接以增强肌萎缩侧索硬化症患者调节性T细胞的抑制活性
Biomedicines. 2024 May 7;12(5):1022. doi: 10.3390/biomedicines12051022.
3
New Insights into Oxidative Stress and Inflammatory Response in Neurodegenerative Diseases.神经退行性疾病中氧化应激和炎症反应的新见解
Int J Mol Sci. 2024 Feb 26;25(5):2698. doi: 10.3390/ijms25052698.
4
Potential of neuroimaging as a biomarker in amyotrophic lateral sclerosis: from structure to metabolism.神经影像学作为肌萎缩侧索硬化症生物标志物的潜力：从结构到代谢。
J Neurol. 2024 May;271(5):2238-2257. doi: 10.1007/s00415-024-12201-x. Epub 2024 Feb 17.
5
Neuroprotective effect of the RNS60 in a mouse model of transient focal cerebral ischemia.RNS60 对短暂性局灶性脑缺血小鼠模型的神经保护作用。
PLoS One. 2024 Jan 2;19(1):e0295504. doi: 10.1371/journal.pone.0295504. eCollection 2024.
6
NanoBubble-Mediated Oxygenation: Elucidating the Underlying Molecular Mechanisms in Hypoxia and Mitochondrial-Related Pathologies.纳米气泡介导的氧合作用：阐明缺氧和线粒体相关病理中的潜在分子机制
Nanomaterials (Basel). 2023 Nov 30;13(23):3060. doi: 10.3390/nano13233060.
7
Advances on Cellular Clonotypic Immunity in Amyotrophic Lateral Sclerosis.肌萎缩侧索硬化症细胞克隆型免疫研究进展
Brain Sci. 2022 Oct 20;12(10):1412. doi: 10.3390/brainsci12101412.
8
Effect of RNS60 in amyotrophic lateral sclerosis: a phase II multicentre, randomized, double-blind, placebo-controlled trial.RNS60 在肌萎缩侧索硬化症中的作用：一项 II 期多中心、随机、双盲、安慰剂对照试验。
Eur J Neurol. 2023 Jan;30(1):69-86. doi: 10.1111/ene.15573. Epub 2022 Oct 7.
9
Neuroinflammation in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia and the Interest of Induced Pluripotent Stem Cells to Study Immune Cells Interactions With Neurons.肌萎缩侧索硬化症和额颞叶痴呆中的神经炎症以及诱导多能干细胞在研究免疫细胞与神经元相互作用方面的意义。
Front Mol Neurosci. 2021 Dec 14;14:767041. doi: 10.3389/fnmol.2021.767041. eCollection 2021.
10
Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.免疫与肌萎缩侧索硬化症的相互作用：临床影响。
Neurosci Biobehav Rev. 2021 Aug;127:958-978. doi: 10.1016/j.neubiorev.2021.06.027. Epub 2021 Jun 19.
本文引用的文献
1
Integrated magnetic resonance imaging and [ C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis.肌萎缩侧索硬化症的磁共振成像与[ C]-PBR28 正电子发射断层扫描成像的整合。
Ann Neurol. 2018 Jun;83(6):1186-1197. doi: 10.1002/ana.25251.
2
RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue.RNS60 通过保护神经胶质细胞和周围神经来发挥治疗作用，对 SOD1 ALS 模型小鼠有效。
J Neuroinflammation. 2018 Mar 1;15(1):65. doi: 10.1186/s12974-018-1101-0.
3
Imaging of glia activation in people with primary lateral sclerosis.原发性侧索硬化症患者的神经胶质细胞激活的影像学研究。
Neuroimage Clin. 2017 Oct 25;17:347-353. doi: 10.1016/j.nicl.2017.10.024. eCollection 2018.
4
Upregulation of Myelin Gene Expression by a Physically-Modified Saline via Phosphatidylinositol 3-Kinase-Mediated Activation of CREB: Implications for Multiple Sclerosis.通过磷酯酰肌醇 3-激酶介导的 CREB 激活上调髓鞘基因表达：对多发性硬化症的影响。
Neurochem Res. 2018 Feb;43(2):407-419. doi: 10.1007/s11064-017-2435-1. Epub 2017 Nov 15.
5
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.依达拉奉在明确诊断的肌萎缩侧索硬化症患者中的安全性和有效性：一项随机、双盲、安慰剂对照试验。
Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
6
ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity.肌萎缩侧索硬化症（ALS）患者的调节性 T 淋巴细胞功能失调，与疾病进展速度和严重程度相关。
JCI Insight. 2017 Mar 9;2(5):e89530. doi: 10.1172/jci.insight.89530.
7
The changing picture of amyotrophic lateral sclerosis: lessons from European registers.肌萎缩侧索硬化症的变化图景：来自欧洲登记处的经验教训。
J Neurol Neurosurg Psychiatry. 2017 Jul;88(7):557-563. doi: 10.1136/jnnp-2016-314495. Epub 2017 Mar 11.
8
Nebulization of RNS60, a Physically-Modified Saline, Attenuates the Adoptive Transfer of Experimental Allergic Encephalomyelitis in Mice: Implications for Multiple Sclerosis Therapy.RNS60（一种经过物理改性的生理盐水）雾化吸入可减轻小鼠实验性自身免疫性脑脊髓炎的过继转移：对多发性硬化症治疗的启示。
Neurochem Res. 2017 May;42(5):1555-1570. doi: 10.1007/s11064-017-2214-z. Epub 2017 Mar 7.
9
Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis.胶质细胞激活与肌萎缩侧索硬化症中的结构异常共定位。
Neurology. 2016 Dec 13;87(24):2554-2561. doi: 10.1212/WNL.0000000000003427. Epub 2016 Nov 11.
10
Potential Benefit of the Charge-Stabilized Nanostructure Saline RNS60 for Myelin Maintenance and Repair.电荷稳定纳米结构盐水 RNS60 对髓鞘维持和修复的潜在益处。
Sci Rep. 2016 Jul 25;6:30020. doi: 10.1038/srep30020.
Zotero 插件